Takeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025. In the quarter to June 2026, revenue grew 1.71%, EPS fell 4.35%, free cash flow fell 95.6% and total debt fell 2.58%, each against the same quarter a year earlier.
Follow TAK
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income |
(1,004.02) | 713.74 | 994.96 | 2,346.08 | 2,048.48 | 3,536.01 | 407.47 | 981.13 | 1,680.37 | 1,074.27 |
Depreciation & Amortization |
4,759.44 | 5,025.21 | 5,023.21 | 4,916.56 | 5,190.04 | 5,260.91 | 5,369.57 | 2,452.01 | 1,639.14 | 2,071.92 |
Non Cash Items (Other) |
2,393.44 | 2,689.72 | 2,137.23 | 2,188.38 | 2,760.77 | (345.84) | 1,392.78 | (96.04) | 42.20 | (849.55) |
Accounts Receivable Change |
(463.10) | (389.13) | 104.22 | 555.94 | 1,132.92 | (87.57) | (320.40) | (120.44) | (5.82) | (347.03) |
Change in inventories |
(404.53) | (230.82) | (798.63) | (585.75) | (410.72) | 244.19 | 1,264.93 | 528.10 | 123.47 | 36.14 |
Accounts Payable Change |
(20.79) | (46.98) | (68.28) | (627.55) | 1,113.90 | 344.23 | (275.37) | (147.72) | 61.76 | 395.78 |
Change in other assets and liabilities |
1,895.73 | 275.07 | (1,055.87) | (186.55) | (958.51) | 2,091.49 | 201.83 | 423.57 | (58.77) | 428.14 |
Other operating activities |
(282.71) | (1,059.43) | (1,394.07) | (1,376.15) | (881.22) | (1,540.67) | (1,879.08) | (1,064.30) | (81.67) | (378.98) |
Operating Cash Flow |
6,873.45 | 6,977.40 | 4,942.77 | 7,230.96 | 9,995.64 | 9,502.75 | 6,161.72 | 2,956.31 | 3,400.69 | 2,430.68 |
Capital expenditures |
(1,119.02) | (1,324.73) | (1,151.02) | (1,033.74) | (1,080.79) | (608.68) | (1,053.44) | (242.64) | (576.36) | (545.51) |
Change in intangibles (net) |
(1,575.13) | (1,180.28) | (2,106.64) | (3,648.44) | (558.79) | (1,177.46) | (833.78) | (507.93) | (551.31) | (468.41) |
Net Aquisitions |
219.95 | 135.67 | 137.72 | 58.89 | (191.14) | 4,985.65 | 4,201.24 | (25,861.99) | 510.77 | (4,880.07) |
Long-Term Investments Change (Net) |
(56.81) | (75.29) | 8.66 | 89.56 | 76.36 | 582.88 | 385.03 | 431.42 | 214.74 | (63.59) |
Other investing activities |
94.68 | 22.02 | (89.36) | 41.17 | (8.97) | (83.20) | (11.56) | 659.86 | (437.91) | (140.32) |
Investing cash flow |
(2,436.33) | (2,422.60) | (3,200.65) | (4,492.55) | (1,763.31) | 3,699.18 | 2,687.50 | (25,521.28) | (840.08) | (6,097.93) |
Repayment/Issuance of Debt (Net) |
7.10 | (2,074.47) | 10.44 | (2,109.52) | (5,344.25) | (6,208.74) | (5,392.03) | 28,453.54 | (1,378.22) | 4,421.54 |
Equity Repurchase (Common, Net) |
(340.58) | (342.28) | (16.05) | (199.27) | (690.03) | (20.13) | (34.38) | (10.55) | (168.80) | (214.99) |
Dividends Paid (Total) |
(2,058.55) | (1,996.49) | (1,981.60) | (2,067.68) | (2,524.62) | (2,663.56) | (2,599.75) | (1,286.57) | (1,277.04) | (1,317.70) |
Other financial activities |
(886.98) | (546.16) | (458.26) | (871.22) | (966.47) | (1,338.11) | (1,221.80) | (640.29) | (111.97) | (192.82) |
Financing cash flow |
(3,279.01) | (4,959.40) | (2,445.47) | (5,247.69) | (9,525.36) | (10,230.53) | (9,247.96) | 26,516.13 | (2,936.03) | 2,696.03 |
Exchange Rate Adjustment |
227.52 | (75.14) | 180.81 | 169.67 | 255.95 | 117.51 | (200.25) | (281.42) | (41.08) | (53.41) |
Discontinued Operations and Adjustments |
— | — | — | — | — | — | 5.79 | — | 196.17 | (202.71) |
Change in Cash |
1,385.61 | (479.73) | (522.54) | (2,339.62) | (1,037.09) | 3,088.92 | (598.99) | 3,669.74 | (220.34) | (1,227.33) |
Beginning Cash |
2,541.75 | 3,021.48 | 3,681.36 | 6,287.74 | 8,599.38 | 5,993.57 | 6,465.04 | 2,654.76 | 2,875.10 | 4,198.26 |
Ending Cash |
3,927.36 | 2,541.75 | 3,158.82 | 3,948.12 | 7,562.29 | 9,082.49 | 5,866.05 | 6,324.50 | 2,654.76 | 2,970.93 |
Stock Based Compensation |
480.32 | 480.92 | 489.01 | 448.97 | 386.03 | 354.03 | 267.92 | 180.76 | 167.49 | — |
Dividends Paid (Common) |
(2,058.55) | (1,996.49) | (1,981.60) | (2,067.68) | (2,524.62) | (2,663.56) | (2,599.75) | (1,286.57) | (1,277.04) | (1,317.70) |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Assets Liabilities Change (Total) |
1,007.31 | (391.86) | (1,818.56) | (843.91) | 877.58 | 2,592.34 | 870.98 | 683.51 | 120.64 | 513.03 |
Investments Change (Net) |
(56.81) | (75.29) | 8.66 | 89.56 | 76.36 | 582.88 | 385.03 | 431.42 | 214.74 | (63.59) |
Issuance/Purchase of Shares |
(340.58) | (342.28) | (16.05) | (199.27) | (690.03) | (20.13) | (34.38) | (10.55) | (168.80) | (214.99) |
| Other line items | ||||||||||
Revenue per Employee |
0.63 | 0.64 | 0.60 | 0.61 | 0.67 | 0.64 | 0.64 | 0.38 | 0.59 | 0.59 |